Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00954356 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

A Phase 2 study of Dental Pain, sponsored by Xenon Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
61
Enrollment target
1
Study location

NCT00954356: Completed Phase 2 study of Dental Pain, sponsored by Xenon Pharmaceuticals.

NCT00954356 is a Phase 2 study of Dental Pain that has completed, run by Xenon Pharmaceuticals. The registered enrollment target is 61 participants, below the 235-participant average among 6 other Dental Pain trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00954356, a Phase 2 study of Dental Pain, has completed, sponsored by Xenon Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

The purpose of this trial is to determine if XPF-001 is effective for the treatment of pain following third-molar/wisdom tooth extraction.

Primary Outcome

The primary efficacy variable was total pain relief at the 6-hour observation (TOTPAR 6); TOTPAR 6 is an area calculation incorporating time and relief scores over the 6 hours following dosing and was calculated using Simpson's trapezoidal rule. The higher the LS Means scores, the more pain relief was obtained. Relief (REL) scores were measured at multiple timepoints after dosing, using a 5 point categorical pain relief rating scale. (None = 0, A Little Relief = 1, Some = 2, A Lot = 3, Complet

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG XPF-001

Study Locations (1)

Utah

  • Jean Brown Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2009-09
Est. Completion 2009-12
Phase Phase 2
Xenon Pharmaceuticals

13 total trials

What the finished NCT00954356 record still lists

NCT00954356 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 235-participant average among 6 other Dental Pain trials with a reported enrollment target (74% lower).

The record links to 1 condition, with Dental Pain appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00954356 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT00954356 about?

NCT00954356 is a clinical study titled "Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction". The purpose of this trial is to determine if XPF-001 is effective for the treatment of pain following third-molar/wisdom tooth extraction.

What is the current status of trial NCT00954356?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2009-09. Estimated completion is 2009-12.

What conditions does trial NCT00954356 study?

This clinical trial studies the following conditions: Dental Pain.

What interventions are being tested in trial NCT00954356?

The interventions under investigation include: placebo (DRUG), XPF-001 (DRUG).

Who is sponsoring clinical trial NCT00954356?

This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00954356 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dental Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04115306 · 61 participants · Phase 1

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

  • NCT05070845 · 61 participants · Phase 2

    Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  • NCT05187832 · 61 participants · Phase 1

    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

  • NCT05269316 · 61 participants · Phase 1

    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00954356, the US trial registry maintained by the National Library of Medicine. NCT00954356 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.